UA113522C2 - Склади дезоксихолевої кислоти та її солей - Google Patents

Склади дезоксихолевої кислоти та її солей Download PDF

Info

Publication number: UA113522C2
Authority: UA; Ukraine
Prior art keywords: pharmaceutical composition; aqueous pharmaceutical; salt; deoxycholic acid; composition according
Prior art date: 2011-08-23

Application number

UAA201400641A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-08-23

Filing date

2011-08-23

Publication date

2017-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45569726&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA113522(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-08-23 Application filed filed Critical

2017-02-10 Publication of UA113522C2 publication Critical patent/UA113522C2/uk

Links

KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 title claims abstract description 133
239000000203 mixture Substances 0.000 title claims abstract description 113
229960003964 deoxycholic acid Drugs 0.000 title claims abstract description 104
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 title claims abstract description 64
150000003839 salts Chemical class 0.000 title claims abstract description 43
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
238000001556 precipitation Methods 0.000 claims abstract description 26
239000000546 pharmaceutical excipient Chemical class 0.000 claims abstract description 11
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 87
239000000243 solution Substances 0.000 claims description 50
238000000034 method Methods 0.000 claims description 37
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
235000019445 benzyl alcohol Nutrition 0.000 claims description 29
239000007864 aqueous solution Substances 0.000 claims description 27
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
239000000872 buffer Substances 0.000 claims description 19
239000011780 sodium chloride Substances 0.000 claims description 12
239000003755 preservative agent Substances 0.000 claims description 10
230000002335 preservative effect Effects 0.000 claims description 9
-1 alkali metal salt Chemical class 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
229910052783 alkali metal Inorganic materials 0.000 claims description 6
239000000126 substance Substances 0.000 claims description 6
159000000000 sodium salts Chemical group 0.000 claims description 5
239000008223 sterile water Substances 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 3
230000000087 stabilizing effect Effects 0.000 claims description 3
239000012752 auxiliary agent Substances 0.000 claims description 2
238000004108 freeze drying Methods 0.000 claims description 2
230000005764 inhibitory process Effects 0.000 claims description 2
235000010469 Glycine max Nutrition 0.000 claims 1
244000068988 Glycine max Species 0.000 claims 1
241001291562 Martes pennanti Species 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
229940126601 medicinal product Drugs 0.000 claims 1
230000035939 shock Effects 0.000 claims 1
230000001755 vocal effect Effects 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 description 27
239000002585 base Substances 0.000 description 21
239000013049 sediment Substances 0.000 description 21
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
150000001875 compounds Chemical class 0.000 description 16
239000002244 precipitate Substances 0.000 description 14
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
239000002253 acid Substances 0.000 description 10
238000002347 injection Methods 0.000 description 10
239000007924 injection Substances 0.000 description 10
229910052751 metal Inorganic materials 0.000 description 10
239000002184 metal Substances 0.000 description 10
210000001789 adipocyte Anatomy 0.000 description 9
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
229940009976 deoxycholate Drugs 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000008363 phosphate buffer Substances 0.000 description 8
239000005557 antagonist Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000010254 subcutaneous injection Methods 0.000 description 7
239000007929 subcutaneous injection Substances 0.000 description 7
239000008186 active pharmaceutical agent Substances 0.000 description 6
210000000577 adipose tissue Anatomy 0.000 description 6
238000009472 formulation Methods 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
239000002464 receptor antagonist Substances 0.000 description 6
229940044551 receptor antagonist Drugs 0.000 description 6
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 5
238000004062 sedimentation Methods 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
239000011734 sodium Substances 0.000 description 5
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 4
UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 4
229940075564 anhydrous dibasic sodium phosphate Drugs 0.000 description 4
229910000019 calcium carbonate Inorganic materials 0.000 description 4
150000004649 carbonic acid derivatives Chemical class 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000008367 deionised water Substances 0.000 description 4
229910021641 deionized water Inorganic materials 0.000 description 4
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 4
239000001095 magnesium carbonate Substances 0.000 description 4
229910000021 magnesium carbonate Inorganic materials 0.000 description 4
229910000000 metal hydroxide Inorganic materials 0.000 description 4
150000004692 metal hydroxides Chemical class 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
230000000861 pro-apoptotic effect Effects 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
229910000029 sodium carbonate Inorganic materials 0.000 description 4
235000017550 sodium carbonate Nutrition 0.000 description 4
239000008215 water for injection Substances 0.000 description 4
239000011667 zinc carbonate Substances 0.000 description 4
235000004416 zinc carbonate Nutrition 0.000 description 4
229910000010 zinc carbonate Inorganic materials 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000034994 death Effects 0.000 description 3
229940061607 dibasic sodium phosphate Drugs 0.000 description 3
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000012064 sodium phosphate buffer Substances 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 3
238000011282 treatment Methods 0.000 description 3
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
210000000593 adipose tissue white Anatomy 0.000 description 2
150000001340 alkali metals Chemical class 0.000 description 2
XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
125000000746 allylic group Chemical group 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
239000013011 aqueous formulation Substances 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
239000003637 basic solution Substances 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
230000003139 buffering effect Effects 0.000 description 2
230000022534 cell killing Effects 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
229940125773 compound 10 Drugs 0.000 description 2
229940125797 compound 12 Drugs 0.000 description 2
229940125782 compound 2 Drugs 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
239000000644 isotonic solution Substances 0.000 description 2
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
238000004321 preservation Methods 0.000 description 2
YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 2
229950001870 spizofurone Drugs 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
VMNRNUNYBVFVQI-OJEXMJBDSA-N (8s,9s,10s,13s,14s)-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 VMNRNUNYBVFVQI-OJEXMJBDSA-N 0.000 description 1
AKUNSTOMHUXJOZ-UHFFFAOYSA-N 1-hydroperoxybutane Chemical compound CCCCOO AKUNSTOMHUXJOZ-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101710151321 Melanostatin Proteins 0.000 description 1
102400000064 Neuropeptide Y Human genes 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
239000004283 Sodium sorbate Substances 0.000 description 1
238000007239 Wittig reaction Methods 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
125000005250 alkyl acrylate group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
229940125714 antidiarrheal agent Drugs 0.000 description 1
239000003793 antidiarrheal agent Substances 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
JHYNXXDQQHTCHJ-UHFFFAOYSA-M ethyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC)C1=CC=CC=C1 JHYNXXDQQHTCHJ-UHFFFAOYSA-M 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000005286 illumination Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000005907 ketalization reaction Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000002366 lipolytic effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
238000006772 olefination reaction Methods 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Obesity (AREA)
Diabetes (AREA)
Hematology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

UAA201400641A 2011-08-23 2011-08-23 Склади дезоксихолевої кислоти та її солей UA113522C2 (xx)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2011/048806 WO2013028177A1 (fr)	2011-08-23	2011-08-23	Préparations d'acide désoxycholique et sels associés

Publications (1)

Publication Number	Publication Date
UA113522C2 true UA113522C2 (xx)	2017-02-10

Family

ID=45569726

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA201400641A UA113522C2 (xx)	2011-08-23	2011-08-23	Склади дезоксихолевої кислоти та її солей

Country Status (18)

Country	Link
JP (1)	JP5919597B2 (fr)
KR (5)	KR101919269B1 (fr)
CN (3)	CN108619089A (fr)
AU (3)	AU2011375432B2 (fr)
BR (1)	BR112014000547B1 (fr)
CA (1)	CA2842177C (fr)
CR (1)	CR20140053A (fr)
EA (1)	EA029305B1 (fr)
IL (1)	IL230547A (fr)
IN (1)	IN2014CN02188A (fr)
MX (1)	MX350390B (fr)
MY (1)	MY184277A (fr)
NZ (1)	NZ620040A (fr)
PH (1)	PH12016501175A1 (fr)
SG (1)	SG2014013205A (fr)
UA (1)	UA113522C2 (fr)
WO (1)	WO2013028177A1 (fr)
ZA (1)	ZA201401027B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8101593B2 (en)	2009-03-03	2012-01-24	Kythera Biopharmaceuticals, Inc.	Formulations of deoxycholic acid and salts thereof
JP2018532806A (ja) *	2015-11-04	2018-11-08	キセラバイオファーマシューティカルズインコーポレイテッド	デオキシコール酸およびその塩による蓄積脂肪の処置方法
KR101841193B1 (ko) *	2016-09-22	2018-03-22	이경락	저장성 지방 분해 조성물 및 그의 제조 방법
US20180078621A1 (en) *	2016-09-22	2018-03-22	Kyoung Lack Lee	Composition for hypotonic lipolysis and manufacturing method thereof
WO2019203511A1 (fr) *	2018-04-16	2019-10-24	주식회사 펜믹스	Composition pharmaceutique d'acide désoxycholique
KR102172439B1 (ko) *	2018-12-05	2020-10-30	송미희	지방 분해용 조성물 및 이를 포함하는 주사제 조성물
KR102064864B1 (ko)	2019-02-08	2020-01-10	(주)제테마	국소 주사용 조성물
KR102111346B1 (ko) *	2019-08-20	2020-05-22	아영창	침전으로부터 안정한 소듐디옥시콜레이트를 포함하는 수용액상 조성물
KR20220026068A (ko)	2020-08-25	2022-03-04	강명범	지방 분해용 주사제 조성물
CN116617160A (zh) *	2023-07-25	2023-08-22	山东则正医药技术有限公司	水性混悬液及制备方法、冻干粉及应用、脂肪消减注射剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2754709B1 (fr)	1996-10-23	1999-03-05	Sanofi Sa	Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
AU758679B2 (en) *	1998-07-24	2003-03-27	Seo Hong Yoo	Preparation of aqueous clear solution dosage forms with bile acids
US6417179B1 (en) *	1998-10-13	2002-07-09	Craig G. Burkhart	Ear wax solution
US20050048126A1 (en) *	2000-12-22	2005-03-03	Barrett Rabinow	Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
DE10361067A1 (de) *	2003-12-22	2005-07-14	Aventis Pharma Deutschland Gmbh	Medikamentöse Lipolyse von Fettansammlungen
MXPA06013437A (es)	2004-05-19	2007-03-23	Los Angeles Biomed Res Inst	Uso de un detergente para la eliminacion no quirurgica de grasa.
US7754230B2 (en)	2004-05-19	2010-07-13	The Regents Of The University Of California	Methods and related compositions for reduction of fat
US20060127468A1 (en)	2004-05-19	2006-06-15	Kolodney Michael S	Methods and related compositions for reduction of fat and skin tightening
AU2006255097B2 (en)	2005-06-06	2012-02-09	Georgetown University	Compositions and methods for lipo modeling
TW201011755A (en)	2008-09-10	2010-03-16	Skymedi Corp	Flash memory system and its data recovery method
JP5420946B2 (ja) *	2009-03-23	2014-02-19	富士フイルム株式会社	胆汁酸を含むミノキシジル水性組成物
EP2645099A1 (fr)	2012-03-30	2013-10-02	Phares Pharmaceutical Research N.V.	Compositions biopertinentes

2011
- 2011-08-23 MX MX2014001495A patent/MX350390B/es active IP Right Grant
- 2011-08-23 CN CN201810400642.9A patent/CN108619089A/zh active Pending
- 2011-08-23 CN CN201180072842.2A patent/CN103826608A/zh active Pending
- 2011-08-23 UA UAA201400641A patent/UA113522C2/uk unknown
- 2011-08-23 WO PCT/US2011/048806 patent/WO2013028177A1/fr active Application Filing
- 2011-08-23 EA EA201490175A patent/EA029305B1/ru unknown
- 2011-08-23 MY MYPI2014000197A patent/MY184277A/en unknown
- 2011-08-23 AU AU2011375432A patent/AU2011375432B2/en active Active
- 2011-08-23 KR KR1020177016779A patent/KR101919269B1/ko active IP Right Grant
- 2011-08-23 BR BR112014000547-8A patent/BR112014000547B1/pt active IP Right Grant
- 2011-08-23 KR KR1020197030233A patent/KR102073536B1/ko active IP Right Grant
- 2011-08-23 JP JP2014527128A patent/JP5919597B2/ja active Active
- 2011-08-23 NZ NZ620040A patent/NZ620040A/en not_active IP Right Cessation
- 2011-08-23 KR KR1020207002722A patent/KR20200013103A/ko not_active Application Discontinuation
- 2011-08-23 IN IN2188CHN2014 patent/IN2014CN02188A/en unknown
- 2011-08-23 SG SG2014013205A patent/SG2014013205A/en unknown
- 2011-08-23 CA CA2842177A patent/CA2842177C/fr active Active
- 2011-08-23 KR KR1020147006855A patent/KR101751585B1/ko active IP Right Review Request
- 2011-08-23 CN CN201810403291.7A patent/CN108743522A/zh active Pending
- 2011-08-23 KR KR1020187032491A patent/KR102034606B1/ko active IP Right Grant
2014
- 2014-01-20 IL IL230547A patent/IL230547A/en active IP Right Grant
- 2014-01-30 CR CR20140053A patent/CR20140053A/es unknown
- 2014-02-10 ZA ZA2014/01027A patent/ZA201401027B/en unknown
2016
- 2016-04-27 AU AU2016202661A patent/AU2016202661B2/en active Active
- 2016-06-16 PH PH12016501175A patent/PH12016501175A1/en unknown
2018
- 2018-04-23 AU AU2018202807A patent/AU2018202807B2/en active Active

Also Published As

Publication number	Publication date
EA201490175A1 (ru)	2014-06-30
KR101919269B1 (ko)	2018-11-15
EA029305B1 (ru)	2018-03-30
AU2016202661B2 (en)	2018-02-22
PH12016501175B1 (en)	2017-12-11
CN103826608A (zh)	2014-05-28
JP2014524467A (ja)	2014-09-22
CN108619089A (zh)	2018-10-09
KR20170075016A (ko)	2017-06-30
JP5919597B2 (ja)	2016-05-18
AU2011375432A1 (en)	2014-02-06
IN2014CN02188A (fr)	2015-05-29
CN108743522A (zh)	2018-11-06
BR112014000547A2 (pt)	2017-02-14
CA2842177C (fr)	2016-07-19
KR102034606B1 (ko)	2019-10-22
KR102073536B1 (ko)	2020-02-04
NZ620040A (en)	2016-06-24
KR20150000448A (ko)	2015-01-02
MY184277A (en)	2021-03-30
BR112014000547B1 (pt)	2021-11-09
AU2016202661A1 (en)	2016-05-19
KR20200013103A (ko)	2020-02-05
CA2842177A1 (fr)	2013-02-28
CR20140053A (es)	2014-06-12
MX2014001495A (es)	2014-04-25
MX350390B (es)	2017-09-06
IL230547A (en)	2017-02-28
KR20190119677A (ko)	2019-10-22
KR101751585B1 (ko)	2017-06-27
IL230547A0 (en)	2014-03-31
WO2013028177A1 (fr)	2013-02-28
AU2011375432B2 (en)	2016-02-04
AU2018202807B2 (en)	2020-01-16
PH12016501175A1 (en)	2017-12-11
SG2014013205A (en)	2014-05-29
AU2018202807A1 (en)	2018-05-10
KR20180123734A (ko)	2018-11-19
ZA201401027B (en)	2017-09-27

Publication	Publication Date	Title
UA113522C2 (xx)	2017-02-10	Склади дезоксихолевої кислоти та її солей
US20210252021A1 (en)	2021-08-19	Formulations of deoxycholic acid and salts thereof
ES2738500T3 (es)	2020-01-23	Formulaciones de ácido desoxicólico y sales del mismo
JP6219430B2 (ja)	2017-10-25	デオキシコール酸およびその塩類の製剤
JP6594486B2 (ja)	2019-10-23	デオキシコール酸およびその塩類の製剤
JP6356329B2 (ja)	2018-07-11	デオキシコール酸およびその塩類の製剤
EP2303228B1 (fr)	2011-11-30	Composition de fosphénytoïne
EA034320B1 (ru)	2020-01-28	Композиции дезоксихолата натрия
JP2946015B2 (ja)	1999-09-06	安定な抗ウィルス点滴用注射剤
KR20210144811A (ko)	2021-11-30	벤조아제핀 화합물-함유 제약 조성물
KR20220062368A (ko)	2022-05-16	p-보로노페닐알라닌을 함유하는 주사액제의 석출 방지 방법